Amyris (NASDAQ:AMRS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Amyris (NASDAQ:AMRS) in a research report released on Friday morning, AnalystRatings.com reports. The brokerage currently has a $11.00 price objective on the biotechnology company’s stock.

Separately, BidaskClub raised shares of Amyris from a sell rating to a hold rating in a research report on Tuesday, August 13th.

Shares of NASDAQ:AMRS traded up $0.19 during trading on Friday, reaching $3.65. 1,456,247 shares of the company’s stock traded hands, compared to its average volume of 956,108. Amyris has a 12 month low of $1.87 and a 12 month high of $8.43. The company has a 50 day moving average of $4.24 and a 200-day moving average of $3.77. The stock has a market capitalization of $377.41 million, a P/E ratio of -1.44 and a beta of 0.92.

Several large investors have recently made changes to their positions in AMRS. American Financial Advisors LLC boosted its stake in Amyris by 31.3% during the 2nd quarter. American Financial Advisors LLC now owns 21,000 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 5,000 shares during the period. Swiss National Bank boosted its stake in Amyris by 8.7% during the 2nd quarter. Swiss National Bank now owns 71,200 shares of the biotechnology company’s stock valued at $253,000 after purchasing an additional 5,700 shares during the period. Rice Hall James & Associates LLC boosted its stake in Amyris by 5.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 188,031 shares of the biotechnology company’s stock valued at $669,000 after purchasing an additional 9,361 shares during the period. Traynor Capital Management Inc. acquired a new position in Amyris during the 2nd quarter valued at about $38,000. Finally, SG Americas Securities LLC acquired a new position in Amyris during the 1st quarter valued at about $28,000. 39.75% of the stock is owned by institutional investors and hedge funds.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Read More: What defines an oversold asset?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.